Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Operating Leases (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Operating Leases for 4 consecutive years, with $22.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 10.55% to $22.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.8 million, a 10.55% decrease, with the full-year FY2024 number at $25.1 million, down 3.27% from a year prior.
  • Operating Leases was $22.8 million for Q3 2025 at Caribou Biosciences, down from $23.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $27.9 million in Q3 2022 to a low of $22.8 million in Q3 2025.
  • A 4-year average of $26.1 million and a median of $26.8 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: grew 2.87% in 2024, then decreased 12.04% in 2025.
  • Caribou Biosciences' Operating Leases stood at $26.8 million in 2022, then decreased by 3.26% to $25.9 million in 2023, then decreased by 3.27% to $25.1 million in 2024, then decreased by 9.11% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Operating Leases are $22.8 million (Q3 2025), $23.6 million (Q2 2025), and $24.3 million (Q1 2025).